Last reviewed · How we verify
Warfarin VKA
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and preventing blood clot formation.
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and preventing blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) treatment and prevention, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | Warfarin VKA |
|---|---|
| Sponsor | Sanofi |
| Drug class | Vitamin K antagonist (VKA); oral anticoagulant |
| Target | Vitamin K epoxide reductase (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Warfarin is a vitamin K antagonist (VKA) that works by inhibiting the recycling of vitamin K, which is essential for the gamma-carboxylation of clotting factors II, VII, IX, and X in the liver. This results in the production of inactive clotting factors and a prolonged prothrombin time (PT/INR). The anticoagulant effect develops over several days as existing clotting factors are cleared from circulation.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (DVT/PE) treatment and prevention
- Mechanical heart valve thromboprophylaxis
- Post-myocardial infarction thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Intracranial hemorrhage
- Gastrointestinal bleeding
- Skin necrosis
- Nausea
Key clinical trials
- Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR (PHASE3)
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy (PHASE4)
- Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
- The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial (PHASE3)
- DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study
- DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial (EARLY_PHASE1)
- Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |